(Total Views: 211)
Posted On: 02/22/2020 7:01:37 AM
Post# of 281
NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces Another Exemplary Addition to its Board
Predictive Oncology (NASDAQ: POAI), a data and artificial intelligence (“AI”) driven discovery services company that provides predictive models of tumor drug response to improve clinical outcomes for patients, today announced that its Board of Directors has unanimously appointed Dan Handley, M.S., Ph.D., to the Board. According to the update, Dr. Handley serves as a professor and the director of the Clinical and Translational Genome Research Institute of Southern California University of Health Sciences. Dr. Handley previously was the chief scientific officer of the Clinical and Translational Genome Research Institute, a Florida 501(c)3 non-profit corporation. “Predictive Oncology is once again very fortunate to announce another exemplary addition to our Board of Directors,” Predictive Oncology CEO Dr. Carl Schwartz said in the news release. “Dan Handley has a varied and strong background, including interaction with Carnegie Mellon University and Magee-Women’s Research Institute both leaders in their respective fields and closely associated with our Helomics division. I greatly anticipate working with Dan and benefitting from his knowledge and experience.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Predictive Oncology (NASDAQ: POAI), a data and artificial intelligence (“AI”) driven discovery services company that provides predictive models of tumor drug response to improve clinical outcomes for patients, today announced that its Board of Directors has unanimously appointed Dan Handley, M.S., Ph.D., to the Board. According to the update, Dr. Handley serves as a professor and the director of the Clinical and Translational Genome Research Institute of Southern California University of Health Sciences. Dr. Handley previously was the chief scientific officer of the Clinical and Translational Genome Research Institute, a Florida 501(c)3 non-profit corporation. “Predictive Oncology is once again very fortunate to announce another exemplary addition to our Board of Directors,” Predictive Oncology CEO Dr. Carl Schwartz said in the news release. “Dan Handley has a varied and strong background, including interaction with Carnegie Mellon University and Magee-Women’s Research Institute both leaders in their respective fields and closely associated with our Helomics division. I greatly anticipate working with Dan and benefitting from his knowledge and experience.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)
